Page 6,418«..1020..6,4176,4186,4196,420..6,4306,440..»

Stem Cell Discoveries Snag Nobel Prize in Medicine

Posted: Published on October 8th, 2012

Two scientists who discovered the developmental clock could be turned back in mature cells, transforming them into immature cells with the ability to become any tissue in the body pluripotent stem cells are being honored with the Nobel Prize in Physiology or Medicine. The Nobel Prize honoring Sir John B. Gurdon and Shinya Yamanaka was announced today (Oct. 8) by the Royal Swedish Academy of Sciences. Th duo's work revealed what scientists had thought impossible. Just after conception, an embryo contains immature cells that can give rise to any cell type such as nerve, muscle and liver cells in the adult organism; these are called pluripotent stem cells, and scientists believed once these stem cells become specialized to carry out a specific body task there was no turning back. Gurdon, now at the Gurdon Institute in Cambridge, England, found this wasn't the case when in 1962 he replaced the nucleus of a frog's egg cell with the nucleus taken from a mature intestinal cell from a tadpole. And voila, the altered frog egg developed into a tadpole, suggesting the mature nucleus held the instructions needed to become all cells in the frog, as if it were a young unspecialized cell. … Continue reading

Posted in Cell Medicine | Comments Off on Stem Cell Discoveries Snag Nobel Prize in Medicine

Stem cell experts win Nobel prize

Posted: Published on October 8th, 2012

8 October 2012 Last updated at 09:58 ET By James Gallagher Health and science reporter, BBC News Please turn on JavaScript. Media requires JavaScript to play. British scientist John Gurdon told a news conference he still keeps a bad report given to him by his school science teacher Two pioneers of stem cell research have shared the Nobel prize for medicine or physiology. John Gurdon from the UK and Shinya Yamanaka from Japan were awarded the prize for changing adult cells into stem cells, which can become any other type of cell in the body. Prof Gurdon used a gut sample to clone frogs and Prof Yamanaka altered genes to reprogramme cells. The Nobel committee said they had "revolutionised" science. The prize is in stark contrast to Prof Gurdon's first foray into science when his biology teacher described his scientific ambitions as "a waste of time". "I believe Gurdon has ideas about becoming a scientist; on his present showing this is quite ridiculous; if he can't learn simple biological facts he would have no chance of doing the work of a specialist, and it would be a sheer waste of time, both on his part and of those who would … Continue reading

Posted in Cell Medicine | Comments Off on Stem cell experts win Nobel prize

Stem cell pioneers win Nobel for medicine

Posted: Published on October 8th, 2012

Shinya Yamanaka of Japan and John Gurdon of Britain won the Nobel Prize on Monday for work in cell programming, a frontier that has nourished dreams of replacement tissue for people crippled by disease. The two scientists found that adult cells can be transformed back to an infant state called stem cells, the key ingredient in the vision of regenerative medicine. "Their findings have revolutionised our understanding of how cells and organisms develop," the Nobel jury declared. "By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy." Among those who acclaimed the award were Britain's Royal Society, Ian Wilmut, "father" of Dolly the cloned sheep, and a leading ethicist, who said it eased a storm about the use of embryonic cells. Stem cells are precursor cells which differentiate into the various organs of the body. They have stirred huge excitement, with hopes that they can be coaxed into growing into replacement tissue for victims of Alzheimer's, Parkinson's and other diseases. Gurdon, 79, said he was grateful but also surprised by the honour, since his main research was done a half-century ago. In 1962, he discovered that the DNA code in the … Continue reading

Posted in Cell Medicine | Comments Off on Stem cell pioneers win Nobel for medicine

Cell rewind wins medicine Nobel

Posted: Published on October 8th, 2012

John Gurdon (left) and Shinya Yamanaka showed how to reprogram cells into their embryonic states. J. Player/Rex Features; Aflo/Rex Features The discovery that cells can be reprogrammed to an embryonic-like state has won this years Nobel Prize in Physiology or Medicine for two leading lights of stem-cell research: John Gurdon and Shinya Yamanaka. Reprogrammed cells regain pluripotency, the potential to differentiate into many mature cell types. Many researchers hope that cells created in this way will eventually be used in regenerative medicine, providing replacement tissue for damaged or diseased organs. The field has become one of the hottest in biology, but the prizewinners discoveries were not without controversy when they were made. Gurdon, who is based at the Gurdon Institute in Cambridge, UK, was the first person to demonstrate that cells could be reprogrammed, in work published 50years ago1. At the time, scientists believed that cellular specialization was a one-way process that could not be reversed. Gurdon overturned that dogma by removing the nucleus from a frog egg cell and replacing it with the nucleus from a tadpoles intestinal cell. Remarkably, the process was able to turn back the cellular clock of the substitute nucleus. Although it had already committed … Continue reading

Posted in Cell Medicine | Comments Off on Cell rewind wins medicine Nobel

Cellerant Awarded SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia

Posted: Published on October 8th, 2012

SAN CARLOS, Calif.--(BUSINESS WIRE)-- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503. The SBIR Contract funds the development of CLT-009, a first-in-class, human allogeneic Megakaryocyte Progenitor Cell therapy for the treatment of thrombocytopenia in cancer patients and allows the Company to conduct studies to enable an Investigational New Drug (IND) Application to be filed with the FDA in the next two years. Thrombocytopenia is characterized as a significant reduction in the concentration of circulating platelets. Platelets are crucial in the process of coagulation to stop bleeding, and thrombocytopenia can increase the risk of severe bleeding in patients. It is becoming an increasingly common problem among oncology patients and a significant dose-limiting toxicity, especially in the treatment of hematological malignancies. Chemotherapy and radiation therapy are the most common causes of thrombocytopenia because the platelet-producing cells, megakaryocytes, and their precursors are highly sensitive to myelosuppressive cytotoxics and ionizing radiation. Thrombocytopenia typically occurs during the initial cycles of high-dose chemotherapy … Continue reading

Posted in Cell Therapy | Comments Off on Cellerant Awarded SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia

NeoStem Announces Very Small Embryonic-Like Cells (VSEL(TM)) Publication in Stem Cells and Development

Posted: Published on October 8th, 2012

NEW YORK, Oct. 8, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), an emerging leader in the fast growing cell therapy market, announced today that data from its collaborative studies with the University of Michigan School of Dentistry further expands the therapeutic potential of its proprietary regenerative cell therapy product, "VSELSTM" (very small embryonic-like stem cells), by demonstrating bone regeneration capabilities in a study published online ahead of print1 in the journal Stem Cells and Development (DOI: 10.1089/scd.2012.0327). The paper highlights that human VSEL stem cells form human bone when implanted in the bone tissue of SCID mice. VSELs are a population of stem cells found in adult bone marrow with potential regenerative properties similar to those of embryonic stem cells. NeoStem has shown that these cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what NeoStem believes to be a population of stem cells that have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative effects known to be associated with embryonic stem cells. This published controlled study, funded by NIH and led by Dr. Russell Taichman, Major Ash Collegiate … Continue reading

Posted in Cell Therapy | Comments Off on NeoStem Announces Very Small Embryonic-Like Cells (VSEL(TM)) Publication in Stem Cells and Development

Biopharma with personalized cell therapy raises $45M in stock sale, forges collaboration deal

Posted: Published on October 8th, 2012

A company with the first FDA-approved personalized cell therapy for reducing wrinkles has raised $45 million in a private stock sale. The financing was sought to improve manufacturing capacity for the therapy and advance other uses for it such as treating burn victims, according to a company statement. Fibrocell Sciences aesthetic therapeutic, Laviv, secured got the green light from the U.S. Food and Drug Administration last year. Laviv uses individuals fibroblast cells to reduce nasolabial fold wrinkles, creases on the face that start from the outer corners of the nose and go down to the corners of the mouth. It also has an acne therapy in phase 3 clinical trials and a burn scar therapy in phase 2 trials. The Exton, Pennsylvania biopharmaceutical companys personalized cell development platform technology isolates, purifies and multiplies a patients fibroblast cells, connective skin cells that make collagen. Additionally, Fibrocell agreed to a strategic collaboration with biotechnology firm Intrexon which can provide genome engineering, cell processing, and cell system engineering, among other services, to help advance Fibrocells personalized cell therapy program. As part of the financing deal, Third Security LLC will get two seats on Fibrocells board. Personalized stem cell development fits into the broader … Continue reading

Posted in Cell Therapy | Comments Off on Biopharma with personalized cell therapy raises $45M in stock sale, forges collaboration deal

Human trial of drugs: SC seeks govts' replies

Posted: Published on October 8th, 2012

Taking a serious view of alleged use of human beings as guinea pigs for clinical trials by drug companies, the Supreme Court on Monday asked the Centre and various states governments to reply to the allegation. A bench of justices R M Lodha and A R Dave also directed the Union government to come out with details of the deaths, if any, and the side effects and compensation, if any, paid to the victims or their family members. The apex court's direction came during the hearing of a public interest litigation petition, filed by NGO Swasthya Adhikar Manch, alleging large scale clinical drug trials across the country by various pharmaceutical firms using Indian citizens as guinea pigs in those tests. "We can even issue a one-line direction that all these clinical trials which affect many people must stop forthwith. It must suffice, we are very serious about it," the apex court told Additional Solicitor General Siddharth Luthra. The bench while expressing its serious concern, however, refrained from passing any blanket ban on the trials and instead sought a comprehensive reply from the Centre on the four issues. The issues included number of applications received by the Union government for clinical … Continue reading

Posted in Drug Side Effects | Comments Off on Human trial of drugs: SC seeks govts' replies

SC seeks govts' replies on human trial of drugs

Posted: Published on October 8th, 2012

Taking a serious view of alleged use of human beings as guinea pigs for clinical trials by drug companies, the Supreme Court on Monday asked the Centre and various states governments to reply to the allegation. A Bench of Justices R M Lodha and A R Dave also directed the Union government to come out with details of the deaths, if any, and the side effects and compensation, if any, paid to the victims or their family members. The apex court's direction came during the hearing of a public interest litigation (PIL) petition, filed by NGO Swasthya Adhikar Manch, alleging large scale clinical drug trials across the country by various pharmaceutical firms using Indian citizens as guinea pigs in those tests. "We can even issue a one-line direction that all these clinical trials which affect many people must stop forthwith. It must suffice, we are very serious about it," the apex court told Additional Solicitor General Siddharth Luthra. The Bench while expressing its serious concern, however, refrained from passing any blanket ban on the trials and instead sought a comprehensive reply from the Centre on the four issues. The issues included number of applications received by the Union government for … Continue reading

Posted in Drug Side Effects | Comments Off on SC seeks govts' replies on human trial of drugs

Fillmore Capital Partners Announces AlixaRx™

Posted: Published on October 8th, 2012

SAN FRANCISCO--(BUSINESS WIRE)-- Fillmore Capital Partners (FCP), a private investment company, today announced the formal launch of AlixaRx, a company that has been in development over the past four years. AlixaRx will provide comprehensive pharmacy services to post-acute and numerous other healthcare settings. AlixaRx leverages cutting-edge technology and advanced clinical pharmacist consulting to improve medication management for patients and deliver significant cost savings to the healthcare system. The current medication management model for post-acute care facilities in particular is inefficient, outdated, and too costly, said Ron Silva, President and CEO of Fillmore Capital Partners. AlixaRx will dramatically change the landscape of the healthcare community by providing all vital medications to patients on-site, while reducing the cost of medications to the payer to a single unit dose cost. AlixaRx will use full-service regional pharmacy hubs, clinical pharmacists, automated dispensing machines, electronic medication cabinets, and advanced clinical software to meet the 24-hour-a-day, seven-day-a-week needs of patients and providers transforming medication management to a science and a high-quality benefit to all. AlixaRxs board-certified, geriatric-specialty, clinical pharmacists will participate as an integral member of each client facilitys interdisciplinary care team to optimize drug therapy for patients and payers. Utilizing AlixaRxs advanced technology platform, clinical … Continue reading

Posted in Wholesale Pharmacy | Comments Off on Fillmore Capital Partners Announces AlixaRx™

Page 6,418«..1020..6,4176,4186,4196,420..6,4306,440..»